Filing Flows › Inovio Pharmaceuticals (INO) › Q4 2024
Inovio Pharmaceuticals (INO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 18, 2025
Inovio Pharmaceuticals (INO) reported revenue of $117K for the fourth quarter 2024 (Q4 2024), +14% from a year earlier.
Inovio Pharmaceuticals, Q4 2024: revenue $117K (+14% year over year), net loss $19.4M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $117K | — | +14% |
| Operating profit | −$20.4M | — | — |
| Net earnings | −$19.4M | — | — |
| Operating cash flow | −$19.7M | — | — |
What changed
Revenue was $117K in Q4 2024, up 14% year over year.
Operating costs exceeded revenue by $20.4M, an operating margin of -17410.8%. Total costs fell 25% while revenue rose 14%. The quarter ended with a net loss of $19.4M.
Operating cash flow was −$19.7M. Non-cash charges added back $417K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $2.0M.
Questions
What was Inovio Pharmaceuticals' revenue in the fourth quarter 2024?
Inovio Pharmaceuticals (INO) reported revenue of $117K for the fourth quarter 2024 (Q4 2024), +14% from a year earlier.